Gadolinium deposition in the brain: association with various GBCAs using a generalized additive model
- 684 Downloads
To determine the relationship between the number of administrations of various gadolinium-based contrast agents (GBCAs) and increased T1 signal intensity in the globus pallidus (GP) and dentate nucleus (DN).
This retrospective study included 122 patients who underwent double-dose GBCA-enhanced magnetic resonance imaging. Two radiologists calculated GP-to-thalamus (TH) signal intensity ratio, DN-to-pons signal intensity ratio and relative change (Rchange) between the baseline and final examinations. Interobserver agreement was evaluated. The relationships between Rchange and several factors, including number of each GBCA administrations, were analysed using a generalized additive model.
Six patients (4.9%) received linear GBCAs (mean 20.8 number of administration; range 15–30), 44 patients (36.1%) received macrocyclic GBCAs (mean 26.1; range 14–51) and 72 patients (59.0%) received both types of GBCAs (mean 31.5; range 12–65). Interobserver agreement was almost perfect (0.99; 95% CI: 0.99–0.99). Rchange (DN:pons) was associated with gadodiamide (p = 0.006) and gadopentetate dimeglumine (p < 0.001), but not with other GBCAs. Rchange (GP:TH) was not associated with GBCA administration.
Previous administration of linear agents gadoiamide and gadopentetate dimeglumine is associated with increased T1 signal intensity in the DN, whereas macrocyclic GBCAs do not show an association.
• Certain linear GBCAs are associated with T1 signal change in the dentate nucleus.
• The signal change is related to the administration number of certain linear GBCAs.
• Difference in signal change may reflect differences in stability of agents.
KeywordsGadolinium Magnetic resonance imaging Dentate nucleus Globus pallidus Contrast media
Estimated glomerular infiltration rate
Generalized additive model
Gadolinium-based contrast agent
Magnetic resonance imaging
Nephrogenic systemic fibrosis
Region of interest
Compliance with ethical standards
The scientific guarantor of this publication is Seung-Koo Lee.
Conflict of interest
The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.
The authors state that this work has not received any funding.
Statistics and biometry
One of the authors has significant statistical expertise.
Institutional Review Board approval was obtained.
Written informed consent was waived by the Institutional Review Board.
Retrospective, diagnostic or prognostic study, performed at one institution.
- 8.Kanda T, Fukusato T, Matsuda M, Toyoda K, Oba H, Kotoku J et al (2015) Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology 276:228–232CrossRefPubMedGoogle Scholar
- 9.Errante Y, Cirimele V, Mallio CA, Di Lazzaro V, Zobel BB, Quattrocchi CC (2014) Progressive increase of T1 signal intensity of the dentate nucleus on unenhanced magnetic resonance images is associated with cumulative doses of intravenously administered gadodiamide in patients with normal renal function, suggesting dechelation. Investig Radiol 49:685–690CrossRefGoogle Scholar
- 11.Quattrocchi CC, Mallio CA, Errante Y, Cirimele V, Carideo L, Ax A et al (2015) Gadodiamide and dentate nucleus T1 hyperintensity in patients with meningioma evaluated by multiple follow-up contrast-enhanced magnetic resonance examinations with no systemic interval therapy. Investig Radiol 50:470–472CrossRefGoogle Scholar
- 14.Radbruch A, Weberling LD, Kieslich PJ, Hepp J, Kickingereder P, Wick W et al (2015) High-signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted images: evaluation of the macrocyclic gadolinium-based contrast agent gadobutrol. Investig Radiol 50:805–810CrossRefGoogle Scholar
- 18.Stojanov DA, Aracki-Trenkic A, Vojinovic S, Benedeto-Stojanov D, Ljubisavljevic S (2016) Increasing signal intensity within the dentate nucleus and globus pallidus on unenhanced T1W magnetic resonance images in patients with relapsing-remitting multiple sclerosis: correlation with cumulative dose of a macrocyclic gadolinium-based contrast agent, gadobutrol. Eur Radiol 26:807–815CrossRefPubMedGoogle Scholar
- 19.Murata N, Gonzalez-Cuyar LF, Murata K, Fligner C, Dills R, Hippe D et al (2016) Macrocyclic and other non–group 1 gadolinium contrast agents deposit low levels of gadolinium in brain and bone tissue: preliminary results from 9 patients with normal renal function. Investig Radiol 51:447–453CrossRefGoogle Scholar
- 22.Subedi KS, Takahashi T, Yamano T, Saitoh J, Nishimura K, Suzuki Y et al (2013) Usefulness of double dose contrast-enhanced magnetic resonance imaging for clear delineation of gross tumor volume in stereotactic radiotherapy treatment planning of metastatic brain tumors: a dose comparison study. J Radiat Res 54:135–139CrossRefPubMedGoogle Scholar
- 30.Edwards BJ, Laumann AE, Nardone B, Miller FH, Restaino J, Raisch DW et al (2014) Advancing pharmacovigilance through academic-legal collaboration: the case of gadolinium-based contrast agents and nephrogenic systemic fibrosis-a Research on Adverse Drug Events and Reports (RADAR) report. Br J Radiol 87:20140307CrossRefPubMedPubMedCentralGoogle Scholar
- 34.Robert P, Lehericy S, Grand S, Violas X, Fretellier N, Idee JM et al (2015) T1-weighted hypersignal in the deep cerebellar nuclei after repeated administrations of gadolinium-based contrast agents in healthy rats: difference between linear and macrocyclic agents. Investig Radiol 50:473–480CrossRefGoogle Scholar
- 41.Ramalho J, Semelka RC, AlObaidy M, Ramalho M, Nunes RH, Castillo M (2016) Signal intensity change on unenhanced T1-weighted images in dentate nucleus following gadobenate dimeglumine in patients with and without previous multiple administrations of gadodiamide. Eur Radiol 26:4080–4088CrossRefPubMedGoogle Scholar